BALAXI PHARMACEUTICALS share news, announcements and annual reports
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.15down ₹0.56 (2.84%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹19.71.
30 Oct: open ₹19.99, high ₹19.99, low ₹18.70
52-week range of traded prices to 30 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 43.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 21,37768.9% delivered
BALAXI PHARMACEUTICALS share news and announcements
466 announcements, routine notices left out, newest first. Page 2 of 10.
Mar 2025
10 Mar · Legal
The exchange asked on 10 Mar 2025
Feb 2025
25 Feb · Meeting
10 Feb · Results
10 Feb · Business
10 Feb · Updates
10 Feb · Board meeting
10 Feb · Results
Nov 2024
15 Nov · Rating
7 Nov · Meeting
5 Nov · Business
5 Nov · Board meeting
5 Nov · Results
Oct 2024
7 Oct · Meeting
Sep 2024
Aug 2024
23 Aug · Meeting
2 Aug · Business
2 Aug · Board meeting
2 Aug · Results
Jul 2024
31 Jul · Updates
31 Jul · Meeting
25 Jul · Board meeting
Jun 2024
May 2024
29 May · Management
29 May · Business
29 May · Board meeting
29 May · Results
21 May · Board meeting
9 May · Corporate action
8 May · Management
Apr 2024
Mar 2024
15 Mar · Meeting
14 Mar · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Consolidated limited review report not submitted. The response of the Company is awaited.
Feb 2024
28 Feb · Amendment to AOA/MOA